Afadin/AF6, an F-actin-binding protein, is ubiquitously expressed in epithelia and has a key role during development, through its regulatory role in cell-cell junction organization. Afadin loss of expression in 15% of breast carcinoma is associated with adverse prognosis and increased risk of metastatic relapse. To determine the role of afadin in breast cancer, we studied the functional consequences of afadin protein extinction using in vitro and in vivo models. Three different breast cancer cell lines representative of the major molecular subtypes were stably repressed for afadin expression (knockdown of afadin (afadin KD)) using RNA interference. Collective and individual migrations as well as Matrigel invasion were markedly increased in afadin KD cells. Heregulin-b1 (HRG-b1)-induced migration and invasion were increased by twofold in afadin KD cells. Conversely, ectopic expression of afadin in the afadin-negative T47D cell line inhibited spontaneous and HRG-b1-induced migrations. RAS/MAPK and SRC kinase pathways were activated in afadin KD cells. Activation levels positively correlated with migration and invasion strength. Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion. Afadin extinction in the SK-BR-3 cell line markedly accelerated tumor growth development in mouse mammary gland and lung metastasis formation. These results may explain why the loss of afadin expression in tumors correlates with high tumor size and poor metastasis-free survival in patients.
Afadin/AF6, an F-actin-binding protein, is ubiquitously expressed in epithelia and has a key role during development, through its regulatory role in cell-cell junction organization. Afadin loss of expression in 15% of breast carcinoma is associated with adverse prognosis and increased risk of metastatic relapse. To determine the role of afadin in breast cancer, we studied the functional consequences of afadin protein extinction using in vitro and in vivo models. Three different breast cancer cell lines representative of the major molecular subtypes were stably repressed for afadin expression (knockdown of afadin (afadin KD)) using RNA interference. Collective and individual migrations as well as Matrigel invasion were markedly increased in afadin KD cells. Heregulin-b1 (HRG-b1)-induced migration and invasion were increased by twofold in afadin KD cells. Conversely, ectopic expression of afadin in the afadin-negative T47D cell line inhibited spontaneous and HRG-b1-induced migrations. RAS/MAPK and SRC kinase pathways were activated in afadin KD cells. Activation levels positively correlated with migration and invasion strength. Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion. Afadin extinction in the SK-BR-3 cell line markedly accelerated tumor
Introduction
Breast cancer is a heterogeneous disease. Different molecular subtypes of breast tumors have been defined, leading to improvement of classification and prognosis (Sorlie et al., 2001) . Despite this, adverse evolution can still be observed for patients with apparent good prognosis at diagnosis and vice versa. New molecular markers that help define prognosis are needed. We previously showed that afadin expression is lost in 15% of breast cancer irrespective of the molecular subtype (Letessier et al., 2007) . We further found that afadin is an independent adverse prognosis factor for patients without axillary lymph node invasion. Absence of afadin expression in tumors correlates with reduced 5-year metastasis-free survival (MFS).
The MLLT4 gene encoding afadin is located on chromosome 6 band q27 (Saha et al., 1995) . No paralog gene exists in mammals. Loss of afadin expression in breast tumors correlates with break at the FRA6E common fragile site located at 6q26 (Letessier et al., 2007) . Afadin is a multidomain F-actin-binding protein expressed in almost all epithelial tissues, and in a variety of other cell types including neurons, fibroblasts, endothelial and epithelial cells (Mandai et al., 1997; Takai et al., 2008) . From the N-to C-terminus, the long isoform of afadin comprises two RAS/RAP1 binding, a Forkhead, a Dilute, a PDZ and an actin-binding domains (Hofmann and Bucher, 1995; Ponting, 1995; Mandai et al., 1997; Linnemann et al., 1999; Yamamoto et al., 1999) . The short isoform lacks the actin-binding domain (Saito et al., 1998) . Afadin role is complex, and still not precisely known. Afadin interacts with various proteins (receptor tyrosine kinases, cell adhesion molecules, cytoskeletal components, regulatory and signaling molecules). Studies of afadin have been carried out in different species, at different developmental stages and in different cellular models in vitro. In mouse, afadin knockout results in embryonic lethality with defects starting at gastrulation. This includes disorganization of the ectoderm, impaired migration of the mesoderm and loss of somites (Ikeda et al., 1999; Zhadanov et al., 1999) . In Drosophila, afadin homolog Canoe (Cno) (Miyamoto et al., 1995) is essential during morphogenesis to maintain adherens junctions by connecting adherens junctions to actin (Sawyer et al., 2009) . However, in contrast to mammals, Cno is dispensable for cadherin-catenin-based adherens junctions assembly and establishment of cell polarity in the fly (Sawyer et al., 2009) . Cno contributes to regulate signal transduction during morphogenesis and genetically interacts with RAS, JNK, NOTCH and WNT pathways (Miyamoto et al., 1995; Takahashi et al., 1998; Matsuo et al., 1999; Boettner et al., 2003; Carmena et al., 2006) . Cno regulates cell shape changes during dorsal closure, asymmetric divisions and cell fate choice (Takahashi et al., 1998; Carmena et al., 2006; Speicher et al., 2008) . The precise mechanisms that support afadin and Cno function are still obscure, but the data have assigned a role for afadin in cell-cell adhesion and/or in the regulation of signal transduction. Afadin has also been described as a regulator of integrin-mediated cell adhesion (Su et al., 2003) . More recently, afadin has been described as a regulator of cell migration. However, afadin contribution as positive or negative regulator of migration is still largely controversial (Lorger and Moelling, 2006; Miyata et al., 2009; Severson et al., 2009) . The role of afadin in oncogenesis has been documented in some acute lymphoid and myeloid leukemias. The MLLT4 gene is a fusion partner of the mixed lineage leukemia gene MLL (Prasad et al., 1993) . Selfassociation of afadin activates the oncogenic potential of MLL-afadin fusion protein (Liedtke et al., 2010) .
To determine the functional consequences of afadin loss of expression in breast cancer physiopathology, we studied in vitro and in vivo models. We inhibited afadin expression in breast tumor cells expressing afadin using RNA interference (RNAi). We demonstrated that stable knockdown of afadin (afadin KD) expression led to a marked increase in collective and individual cell migrations, as well as invasion. In afadin KD cells, increased migration and invasion were concomitant and dependent of the activation of the RAS/MAPK and SRC kinase pathways. In vivo, afadin extinction led to accelerated tumor growth development in mouse mammary gland and lung metastasis formation. Our results assigned afadin as a new breast cancer biomarker involved in tumor progression.
Results

Afadin knockdown using miRNA sequences
To analyze the functional consequences of afadin loss of expression, we used an RNAi strategy. This was done using an expression vector that enables the expression of engineered microRNA (miRNA) sequences and Emerald GFP (EmGFP) as reporter (Letessier et al., 2007) . Three different afadin miRNA sequences were designed and cloned in this vector. These miRNA sequences were located at positions 2515 (AF6-1), 3481 (AF6-2) and 4088 (AF6-3) in the afadin cDNA sequences. Validations of the respective vectors were done in Cos cells after transient expression (data not shown). Because afadin loss of expression in breast tumors is not correlated with any molecular subtype, we selected three cell lines representative of different breast cancer subtypes: MCF7 (luminal), SK-BR-3 (ERBB2) and MDA-MB-231 (basal) cell lines.
Two isoforms of afadin have been described in rodents and humans: a 220-kDa isoform containing the F-actin-binding domain and a 190-kDa isoform missing the F-actin-binding domain (Mandai et al., 1997) . The latter is usually less frequently expressed than the former. Because functional differences have been reported between these two isoforms (Buchert et al., 2007) we first characterized the isoforms of our cellular models. We used two different antibodies. One was directed against the C-terminus F-actin-binding domain and thus specific for the 220-kDa isoform. The other, directed against the PDZ domain, recognized both isoforms. Both antibodies revealed a major band at 220 kDa, suggesting that the 220-kDa isoform is prominently expressed in the three cell lines (Figure 1a) . The knockdown expression of afadin in the three cell lines was equally detected by both antibodies. This ascertained the specificity of the engineered miRNA vectors and the two antibodies ( Figure 1a ). Afadin knockdown efficiency was quantified for the three different miRNAs in the three cell lines. Residual expression of afadin after knockdown ranged from 12 to 38% for MCF7, from 0.5 to 37% for SK-BR-3 and from 33 to 67% for MDA-MB-231 (Figure 1b) . Immunofluorescence analysis showed that expression was homogeneously inhibited within every cell population (data not shown).
Afadin negatively controls 'collective' cell migration Afadin loss of expression in breast cancer correlates with high pathological size and reduced 5-year MFS. This suggests that afadin loss may lead to the deregulation of different biological processes such as proliferation, Figure 1 (a) Afadin knockdown in breast tumor cell lines was obtained by stable RNAi strategy. SK-BR-3, MCF7 and MDA-MB-231 cell lines were tested by western blot using two different monoclonal antibodies. Top: the anti-AF6 (BD) directed against the PDZ domain of afadin. Bottom: the anti-AF6 (HBT) directed against the last C-terminus amino-acid residues present in the long isoform. Both antibodies were used at a concentration of 1 mg/ml, gave similar pattern and revealed the 220-kDa long isoform of afadin. (À): miRNA LacZ control vector; ( þ ): miRNA afadin vector. The P85 regulatory subunit of phosphoinositide-3 kinase was used as loading charge control. (b) Afadin knockdown using three different miRNA afadin vectors (1, 2 and 3) gave variable levels of inhibition compared with the miRNA LacZ control vector (4). Afadin extinction level in cell population was controlled to be homogenous based on GFP signal, and immunofluorescence studies using anti-afadin antibody (data not shown). adhesion and migration. To test these hypotheses, we developed different assays using the three cell lines expressing variable levels of afadin. We thus expected to observe a gradual relationship between phenotype and afadin expression level.
To measure the migration properties of cells, we first used the haptotaxis wound-closure assay that provides insights into 'collective' cell motility. Speed of wound recovery was measured by time-lapse videomicroscopy at 16 h post-wound for MCF7 and SK-BR-3 and 7 h post-wound for MDA-MB-231. These time periods limit artefacts of wound closure due to an expanding population rather than motility. We found similar results for the three cell lines tested, that is, an increase of the velocity of wound closure ranging from 20 to 180% compared with control cells (Figure 2 ). Noticeably, speed of wound recovery was inversely correlated with afadin extinction level, especially in MCF7 and SK-BR-3 cells. Indeed, MCF7 AF6-2 and AF6-3, which had the lowest levels of afadin, showed the highest velocity of wound closure (Figure 2a ). The same was true for SK-BR-3 AF6-1 and AF6-3. The MDA-MB-231 cell line is intrinsically highly motile. In this cell line, afadin KD led to a significant increase of the velocity of wound closure. The whole of these results and time-lapse videomicroscopy videos are presented in Supplementary Figure S1 . Together, these results established a relationship between afadin expression levels and velocity of wound closure.
Heregulin-b1 (HRG-b1) is a potent inducer of cell migration through ERBB2-dependent activity (Spencer et al., 2000) . To analyze the strength of cell migration in afadin KD cells, we compared the collective migration of SK-BR-3 afadin KD cells with that of SK-BR-3 control cells in the presence of HRG-b1. Using the wound-closure assay, we found that the velocity of wound closure of SK-BR-3 afadin KD cells was similar to that of non-KD cells treated with 1 nM HRG-b1 (Figure 2b ). This concentration gives maximum effect in this test. Interestingly, activation of afadin KD cells with 1 nM HRG-b1 induced an additive effect by increasing velocity of wound closure by twofold compared with HRG-b1 on control cells.
In summary, afadin KD led to (i) increased collective cell migration in three different cellular models, (ii) migration in the low-migrating SK-BR-3 cells and (iii) a twofold increase of HRG-b1-mediated collective cell migration. These results suggest that afadin exerts a negative regulation on spontaneous and inducible collective cell migration.
Afadin negatively controls 'individual' cell migration
The wound-closure assay is related to 'collective' motility. Compared with control SK-BR-3 cells we observed that the morphology of SK-BR-3 afadin KD cells was markedly different during wound closure. SK-BR-3 afadin KD cells adopted morphology of migrating cells, with the formation of lamellipodia structures identified by microtubule cytoskeleton staining by a-tubulin antibody ( Figure 3a) . This difference was also seen in standard cultures. Afadin KD cells had an elongated shape compared with control cells (Figure 3b ). The number of cells with an elongated shape was increased from B20% in control cells to 70% in afadin KD cells (Figure 3c ). Results were similar with the three different afadin KD cells. Addition of HRG-b1 to culture induced the formation of lamellipodia in 100% of afadin KD cells compared with 70% of control cells ( Figure 3c ).
We further analyzed SK-BR-3 cell migration on collagen type I precoated (8 mm) transwell filters and compared afadin KD with control cells. Before incubation in upper chambers, cells were controlled to be individualized. We found that migration of SK-BR-3 control cells was low. Migration was dramatically increased in afadin KD cells, ranging from 2.5-to 6-fold respective to afadin extinction ( Figure 4a ). These results suggest that afadin extinction leads to increase individual cell migration. Analysis of velocity on cells seeded at low density by cell tracking showed that afadin KD cells had an increase velocity compared with control cells (Figure 4b ). No difference in directionality was observed (data not shown). It is of note that, for both tests, correlation between migration and afadin expression levels of SK-BR-3 RNAi AF6-1 and AF6-3 was less marked than for wound-closure experiments. This may be attributed to a variation of afadin extinction at the time of the experiments. Together, these results show that afadin negatively controls individual cell migration.
Afadin expression in afadin-negative breast tumor cells
To further demonstrate that afadin is a negative regulator of migration, we looked for a cellular model with an afadin gene alteration such as the one we found in breast tumors. We screened for afadin-negative breast tumor cell lines associated with an MLLT4 gene deletion. Among 16 cell lines, we found 3 cell lines with no or low level of afadin by western blot, namely SUM159, T47D and ZR75.1 (Figure 5a ). Low expression was found at transcriptional level for these cells (data not shown). Genome analysis using array comparative genomic hybridization showed that one allele of the MLLT4 gene was altered in T47D. This was the alteration we described in tumors and therefore we chose T47D as a model to carry out afadin-related functional studies (Figure 5b ).
Full-length L-afadin cDNA was transduced in this cell line (T47D/afadin) ( Figure 6a ) and spontaneous and HRG-b1-induced migration was measured using the wound-closure assay (Figure 6b) . A 35% reduction of spontaneous collective migration was observed in T47D/ afadin compared with T47D control cells (Figure 6b , histogram bars 1 and 2). T47D/afadin showed a 26% reduction of HRG-b1-induced migration (Figure 6b , histogram bars 3 and 4). Remarkably, comparison of T47D and SK-BR-3 cell lines showed that T47D collectively migrated at a velocity similar to SK-BR-3/ afadin KD and conversely that T47D/afadin migrated similarly to SK-BR-3 (Figure 6c ). These results further demonstrated the role of afadin as an important regulator of cell migration.
Afadin negatively regulates invasion
To further characterize the role of afadin, we compared the Matrigel invasiveness of SK-BR-3 afadin KD cells with that of SK-BR-3 control cells in the presence of a chemotactic gradient of serum. Afadin KD significantly increased by 5.6-fold cell invasiveness as seen in Figure 7a (top) and 7b. As expected, addition of 1 nM HRG-b1 strongly increased invasiveness of control cells. More importantly, this effect was strengthened by 2.7-fold in afadin KD cells (Figure 7a bottom and 7b) . These results demonstrated that loss of afadin expression in SK-BR-3 cells leads to increase invasiveness of the cells. As described for migration, afadin KD strengthened HRG-b1-mediated invasion.
Afadin negatively regulates SRC kinase and RAS/MAPK activation Activation of ERBB2 signaling pathways through HRG-b1 activation leads to the activation of the PI3K, p38/MAPK, RAS/MAPK and SRC kinase pathways (Marone et al., 2004) . The RAS/MAPK and SRC kinase pathways are negatively regulated by afadin (Radziwill et al., 2003 (Radziwill et al., , 2007 Carmena et al., 2006) . These pathways have been implicated in cytoskeleton remodeling, cell motility and invasion (Keely et al., 1997; Klemke et al., 1997; Vadlamudi et al., 1999) . We showed that afadin KD results in increased velocity and invasiveness of the cells in the absence or presence of 1 nM HRG-b1 (Figures 2b and 7b ). These conclusions are also strengthened by the experiments performed on the T47D cell line (Figure 6b ). The enhanced effect observed with 1 nM HRG-b1 is surprising, as this dose is expected to give a full biological response in this assay (Marone et al., 2004) . This may indicate that afadin could control the extent of these biological processes by exerting a permanent negative regulation. We analyzed RAS/MAPK and SRC kinase signaling pathways in SK-BR-3 cells and compared SRC and ERK1/2 activation in control and afadin KD cells, in the absence or presence of 1 nM HRG-b1. We found a significant and reproducible increase in SRC and ERK1/2 activation in non-stimulated afadin KD cells (Figure 8a , topleft panel). As already described by others, stimulation of cells with HRG-b1 leads to an increase of SRC and ERK1/2 activation in control cells. Interestingly, activation levels increased in afadin KD cells (Figure 8a , top-right panel). The strength of SRC and ERK1/2 activation correlated with cell invasiveness, highlighting their probable implication in this process (Figure 8a, bottom) .
To test the implication of these pathways in the afadin-regulated migration processes, we used MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors on afadin KD vs control cells. Used at 5 mM on SK-BR-3 cells, these inhibitors markedly blocked phosphorylation of their targets with a very good specificity (data not shown). As shown in Figure 8b , invasiveness of afadin KD cells was inhibited by 46 and 52% with U0126 and SU6656 treatments, respectively. U0126 treatment led to a 36% inhibition of the migration. SU6656 had no effect on migration (Figure 8c) .
These results suggested that afadin knockdown leads to the activation of ERK1/2 and SRC kinase and to their 'hyperactivation' upon stimulation with HRG-b1. Activation of these pathways is implicated, at least in part, in the increase of invasiveness and migration. Our results assigned afadin as a probable negative regulator of cell migration and invasiveness at least in tumor cells and a putative negative modulator of these pathways.
Afadin loss of expression increases tumor development in xenografted mice
In breast cancer patients, afadin loss of expression correlates with tumor size and reduced 5-year MFS. To further document the oncogenic role of afadin loss of expression, we selected the SK-BR-3 cell line that is poorly tumorigenic in mice. We used two assays. First, we measured colony formation in agar, which is a common method to monitor anchorage-independent growth. Colony formation was slightly but significantly increased in SK-BR-3 afadin KD cells. This was mainly associated with a colony size increase (Figure 9a) . Second, SK-BR-3 afadin KD cells were xenografted orthotopically and compared with control cells. As shown in Figure 9b , afadin knockdown markedly accelerated tumor onset in the mouse mammary gland. The detection of metastases was assessed by bioluminescence. Lung metastases were, respectively, detected between the 12th and the 16th weeks and between the 18th and the 21th weeks in 100% of mice xenografted with SK-BR-3 afadin KD cells and SK-BR-3 control cells. Analyses of viable mice at the 13th week showed a marked luminescent signal in lungs of mice xenografted with SK-BR-3 afadin KD not with control mice (Figure 9c ). Analysis on isolated organs confirmed the presence of metastases in lung and not at other sites (Figure 9d) . Similar results were obtained with MCF7 cells (data not shown).
These results indicated that downregulation of afadin expression contributes to increase tumorigenicity and metastasis formation.
Discussion
Afadin is an independent prognosis marker for breast cancer. Loss of afadin is associated with poor outcome in the population of patients with favorable prognosis (lymph node-negative patients). Afadin-negative tumors have a larger size and patients have a reduced 5-year MFS.
In this study, we have developed and analyzed different models to determine the functional consequences of loss of afadin in breast cancer.
Knockdown of afadin expression in breast tumor cell lines led to an increase of cell migration, cell invasiveness, colony formation and tumor growth in mice. These results are in accordance with the histoclinical status of patients with afadin-negative tumors. They also emphasize a key role of afadin in controlling migration and invasion processes at least in tumor cells. Collective and individual cell migration increase was noted in the three cell lines using three different RNAi sequences, and was inversely correlated with afadin levels. Conversely, complementation of the afadindeficient T47D breast tumor cell line reduced cell migration. It has been shown that the F-actin-binding region of afadin is important to negatively regulate the collective cell migration of the MCF10A breast-derived cell line, through the maintenance of E-cadherindependent intercellular adhesion (Lorger and Moelling, 2006) . In our study, we used breast tumor cell lines that express (MCF7) or not (MDA-MB-231 and SK-BR-3) E-cadherin. We analyzed the junctional localization of E-cadherin and b-catenin in MCF7 cells during wound healing and compared between control and afadin KD cells. We found no qualitative and quantitative difference of E-cadherin and b-catenin localization in the presence or absence of afadin expression (Supplementary Figure S2) . This indicates that, at least in MCF7, the cadherin-catenin complex is not affected by afadin KD and that the increase of collective cell migration is mainly the consequence of increased individual cell migration. Afadin interacts with a-catenin and indirectly with other F-actin-binding proteins that link afadin to E-cadherin/ catenin complex (Takai et al., 2008) . We cannot exclude that loss of afadin expression may influence cell migration through deregulation of E-cadherin/catenin signalization. Together, our results are in line with those of Lorger and Moelling (2006) . We found a significant activation of the SRC kinase and ERK1/2 in afadin KD cells and an 'hyperactivation' upon stimulation with HRG-b1. These results are fully in accordance with the repressive role of afadin or its Afadin loss in breast cancer and tumorigenicity G Fournier et al ortholog Cno on the RAS/MAPK pathway and the negative role on SRC kinase activation in mammalian cells (Radziwill et al., 2003 (Radziwill et al., , 2007 Carmena et al., 2006) . We observed a correlation between the strength of SRC and ERK phosphorylation and strength of biological responses. Inhibition of RAS/MAPK and SRC pathways reduced afadin KD-mediated effects. Together, these results assigned afadin as a key negative regulator of tumor cell migration and invasiveness through regulation of these two pathways. Because afadin negatively regulates the strength of migration and invasion, we studied the status of afadin during HRG-b1 stimulation, that is, expression level and localization. We found no modulation of afadin expression level upon stimulation with 1 nM HRG-b1, showing that afadin is not downregulated during activation ( Figure 8A, top) . During activation, we found a marked localization of afadin at the cell leading edge (Supplementary Figure S3) . Thus, afadin localized at leading edge may control the strength of cell migration and invasiveness by regulating RAS/MAPK and SRC signaling pathways. Afadin is thought to have a key role in the stabilization and maintenance of cellcell junction integrity in polarized epithelial cells by exerting a dual role as a cytoskeletal molecular adaptor and as a negative regulator of RAS/MAPK and SRC kinase (Radziwill et al., 2003 (Radziwill et al., , 2007 . This dual role could also be involved in the control of cell migration. It has been hypothesized that RAS-GTP binding to the RA domain of afadin negatively regulates the RAS/MAPK pathway. This binding is regulated by the BCR kinase (Radziwill et al., 2003) . SRC activity is restricted by binding with the PDZ domain of afadin (Radziwill et al., 2007) . In Drosophila, it has been shown that EGF/ RAS signaling may regulate non-muscle myosin II through Canoe (Gaengel and Mlodzik, 2003) . Thus, interactions with transmembrane, cytoskeletal, regulating and signaling proteins have a pivotal role in the function of this scaffold molecule. It remains to understand how different partners can bind to one specific domain. It is possible that these interactions are finely regulated in a spatio-temporal manner during dynamic processes such as cell-cell junction formation and migration processes. Recently, it has been demonstrated that the RA1 domain of afadin or its ortholog Cno mediates self-association of the MLL-AF6 fusion protein via a region different from RAS interaction (Liedtke et al., 2010) . Thus, multimerization of afadin molecules could be an attractive means by which afadin may exert its role of scaffold molecule. We extended our observations to the colon carcinoma-derived cell line SK-CO-15 and found that knockdown of afadin, with three different RNAi, increased the velocity of these cells (data not shown). This result tends to generalize the impact of loss of afadin expression in tumors. However, for an unclear reason, this result contrasts with a recently published work (Severson et al., 2009 ). This could be attributed to the origin of the cell line used. Like afadin, the expression of several actin-binding proteins (a-actinin, gelsolin, tensin-3 and profilin-1) weakens the phenotype of transformed cells (Tanaka et al., 1995; Nikolopoulos et al., 2000; Zou et al., 2007; Martuszewska et al., 2009) . However, effects can be opposite in non-epithelial cells. For example, whereas profilin-1 depletion increases motility and invasiveness of breast cancer cells, it inhibits motility of normal vascular endothelial cells (Bae et al. 2009 , Zou et al., 2007 , Ding et al., 2006 . Similarly, whereas we found that afadin depletion increases motility of breast and colon cancer cells, a recent study showed that it inhibits directional movement induced by plateletderived growth factor in mouse NIH3T3 fibroblasts (Nakata et al., 2007) . Profilin-1 interacts physically with afadin and it is possible that the two molecules interact also functionally to regulate actin modeling at the leading edge (Boettner et al., 2000) . Our results are close to those described for profilin-1 not only in vitro but also in vivo. Indeed, we have shown for the first time that loss of afadin expression increases Matrigel invasiveness and accelerates orthotopic tumorigenicity and metastasis formation.
Afadin loss of expression contributes to foster the major steps of tumor progression, that is, loss of cell polarity, proliferation and migration through deregulation of master molecular events such as SRC and MAPK activation, F-actin functions and probably other non-elucidated mechanisms. These data assign afadin as a tumor progression suppressor gene and explain why a loss of afadin expression in breast tumors impacts on both migration and tumor growth, translating into high tumor size and poor MFS in patients.
Materials and methods
Vectors for RNAi RNA silencing was done using the BLOCK-iT Pol II RNAi expression vector kit as recommended by the manufacturer (Invitrogen, Carlsbad, CA, USA). Artificial afadin miRNA was cloned in the pcDNA 6.2-GW/EmGFP-miR leading to cocistronic expression of EmGFP with afadin miRNA. Different sequences of afadin miRNA were designed using an algorithm developed by Invitrogen. Sense and antisense DNA sequences were AF6_2515S: TGCTGATCAGGTGCATACTTATCCATG TTTTGGCCACTGACTGACATGGATAAATGCACCTGAT and AF6_2515AS: CCTGATCAGGTGCATTTATCCATGT CAGTCAGTGGCCAAAACATGGATAAGTATGCACCTG ATC, respectively. AF6_3481S: TGCTGAGGACTAGGAGGCTGATTTGCG TTTTGGCCACTGACTGACGCAAATCACTCCTAGTCCT and AF6_3481AS: CCTGAGGACTAGGAGTGATTTGCG TCAGTCAGTGGCCAAAACGCAAATCAGCCTCCTAGT CCTC, respectively. AF6_4088S: TGCTGAATCCATGGACATTCCATCGAGT TTTGGCCACTGACTGACTCGATGGAGTCCATGGATT and AF6_4088AS: CCTGAATCCATGGACTCCATCGAGT CAGTCAGTGGCCAAAACTCGATGGAATGTCCATGGA TTC, respectively. These sequences are located, respectively, at residues 2515, 3481 or 4088 in afadin cDNA and are present in the different afadin isoforms.
Vector for afadin expression Full-length cDNA of human L-afadin was amplified by PCR from the pCDNA3-FLAG-L-AF6 vector and cloned in the pRRL-iGFP-GW lentiviral vector using following primers: GWAF6.5, TCGCTCGGATCACCACCATGGACTAC and GWAF6.3FL, CTCACTTTGTGTTCAGTTCATTC. The resulting pRRL-AF6FL vector was used to produce virion stock (see below).
Cells and culture conditions MCF7, MDA-MB-231, SK-BR-3 and T47D breast carcinoma cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) (heat inactivated 30 min at 56 1C), 1 mM pyruvate, 2 mM L-glutamine, 0.1 mM non-essential amino acid, 10 U/ml penicillin, 10 mg/ml streptomycin (Invitrogen); for MCF7 cells, 10 mg/ml of insulin was added (Invitrogen). Cell lines were maintained in a humidified 5% CO 2 atmosphere at 37 1C.
Cell transfection and cell sorting MCF7, MDA-MB-231 and SK-BR-3 cells were transfected by nucleofection with 2 mg of the pCDmiRAF6-2515, 3481, 4088 or lacZ control plasmid as recommended by the manufacturer (Lonza, Walkersville, MD, USA) and selected in the presence of 5 mg/ml blasticidin (Invitrogen).
High GFP expressing cells were selected using a FACSAria II cell sorter (Becton Dickinson, CA, USA).
Production of lentiviral virions
The virus particles were produced by transient transfection into 293T cells seeded the day before in 10 cm plates with 12 ml culture media, with 8.1 mg of the pRRL-AF6FL vector, 8.1 mg of the packaging construct and 2.7 mg of the construct that express the vesicular stomatitis virus glycoprotein by using the calcium-phosphate method. The following day, cells were fed with 6 ml of Dulbecco's modified eagle medium and further cultured for 24 h. The supernatant was then collected, cleared by centrifugation and passed through a 0.45-mm filter. The supernatant was then concentrated by ultracentrifugation over a 20% sucrose cushion. Viral pellet was resuspended in Dulbecco's phosphate-buffered saline supplemented with 1% glycerol in 1/100 of the initial volume of the viral supernatant, aliquoted and stored at -80 1C. Western blot analysis Cells were lyzed in ice-cold lysis buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 0.2 mM sodium ortho-vanadate and 10% glycerol. 'Complete' Protease Inhibitor Cocktail was added to cold lysis buffer as recommended by the manufacturer (Roche Diagnostics, Meylan, France).
Cell lysates (30 or 60 mg) were separated using NuPAGE 4-12% Novex Bis-Tris gels according to the manufacturer's recommendations (Invitrogen) and transferred onto Hybond-C membrane (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). Membranes were blocked in phosphate buffered saline (PBS) supplemented with 5% milk or 5% bovine serum albumin for 1 h and then incubated with indicated antibodies. After washing, membranes were incubated with the secondary antibody conjugated with horseradish peroxidase (Pierce). The signal was detected using the Amersham ECL system (Amersham Pharmacia Biotech, Uppsala, Sweden).
a-CGH hybridization and analysis DNA digestion, labeling and hybridization on Human Genome CGH 244A Oligo Microarray (Agilent Technologies, Santa Clara, CA, USA) was performed as previously described (Adelaide et al., 2007) . Briefly, 1 mg of DNA for each sample and reference (a mix of DNA from peripheral blood leukocytes of 13 healthy men) was, first digested by AluI and RsaI, then labeled with BioPrime Array CGH Genomic Labeling System (Invitrogen) and hybridized with Oligo aCGH Hybridization Kit (Agilent Technologies). After washing, the slides were scanned on an Agilent Microarray Scanner G2505B, captured images were analyzed with Feature Extraction Software v 10.5.1.1 and created text files were processed with CGH Analytics v 3.4 (Agilent Technologies, Santa Clara, CA, USA) to generate genomic alteration profiles.
Immunofluorescence Cells were plated on coverslips in 10% FCS-RPMI for 24 h and incubated with or without 1 nM heregulin (R&D Systems, Minneapolis, MN, USA) for 30 min. Then, cells were fixed in methanol at À20 1C for 6 min and rinsed in PBS. After blocking in PBS, 10% FCS, cells were incubated overnight with primary antibodies diluted in PBS-10% FCS. After washing in PBS-0.1% Tween-20, primary antibodies were detected using donkey anti-rabbit or anti-mouse Ig secondary antibodies conjugated to Cy3 or Cy5. DNA was stained with 250 ng/ml 4',6-diamidino-2-phenylindole for 2 min. Cells were mounted in Prolong Gold anti-fade reagent (Invitrogen) and examined on an LSM-510 Carl Zeiss confocal microscope.
Wound healing assay MCF7, MDA-MB-231, SK-BR-3 and T47D cells (1 Â 10 5 ) were seeded into culture insert (Ibidi, Martinsried, Germany) in 6-well plates and grown to 100% confluency for 24 h and then serum-starved for 24 h. Culture inserts were carefully removed to create a cell-free gap of 400 mm. After three washes with PBS, the wounded monolayers were then incubated in 10% FCS-RPMI medium in the presence of 1 nM heregulin (R&D Systems). Cells were observed using a fluorescence microscope (Zeiss Axiovert 200, Zeiss Carl Zeiss S.A.S. Microscopy Division, Le Pecq, France). Images of wounded monolayers were acquired for 7 or 16 h (5 or 15 min intervals) using a digital camera (charge-coupled device camera Coolsnap HQ; Photometrics Headquarters (Tucson, AZ, USA)) driven by Metamorph software (Molecular Devices, Downingtown, PA, USA). Three independent experiments were done for each experimental condition. Measurements of cell velocity were calculated using the MetaMorph software.
Cell migration assay in Boyden chamber
The migration of SK-BR-3 cells was assayed using transwell 96-well permeable supports (8 mm-Corning HTS) precoated with rat tail collagen I (25 mg/ml-Roche) as described previously (ALMA). In brief, 0.25 ml of 10% FCS-RPMI medium was added in the well of the culture plate (the bottom compartment). Serum-starved SK-BR-3 cells (5 Â 10 4 ) were suspended in 50 ml of 10% FCS-RPMI medium and seeded to the upper chamber. After incubation at 37 1C for 24 h in a cell culture incubator, the cells that migrated from the top to the bottom compartment were detached by transferring the transwell insert in an opaque 96-feeder well plate containing prewarmed trypsin-EDTA (37 1C). After 30 min of incubation at 37 1C, 10% FCS was added to inactivate trypsin and Celltiter-Glo reagent was added to determine the cell number by luminescence assay. Luminescence was recorded after 10 min of incubation using a microplate luminometer (Fluo Star Optima, BMG Labtech GmbH, Offenburg, Germany). Three independent experiments were done for each experimental condition.
Cell tracking assay Cells plated at low density (5 Â 10 4 ) were seeded in 6-well plates precoated with rat tail collagen I (25 mg/ml-Roche). Individual cell tracking was acquired for 24 h at 5 min intervals using a digital camera driven by MetaMorph software. Three independent experiments were done for each experimental condition. Measurements of cell velocity were calculated using the MetaMorph software.
Invasion assay
The invasion assay was performed using the 24 cell culture inserts with 8 mm pore size membrane coated with Matrigel (BD BioCoat Growth Factor reduced Matrigel Invasion Chamber (Becton Dickinson, MA, USA)). Chemoattractant (10% FCS or 1 nM HRG-b1) was added to the wells and 10 5 cells were loaded in the insert in RPMI 0.1% BSA. Plates were incubated for 72 h at 37 1C. After migration, nonmigratory cells on the upper membrane surface were removed with cotton tipped swabs (four times per insert) and the migratory cells attached to the bottom surface of the membrane were stained for 20 min with 0.2% crystal violet in ethanol (Sigma).
After five washes with 200 ml distilled water, invasive cells were counted with an inverted microscope. Each determination represents the average of three individual experiments done in duplicate.
Soft agar assay
The 96-well plate was covered first with bottom agar (DMEM, 10% FCS with 0.6% agar). Cells were suspended at a density of 3 Â 10 4 cells/ml in top agar (DMEM, 10% FCS with 0.3% agar) and seeded to wells of the 96-well plate. After incubation at 37 1C for 10 days, colonies were quantified using CellTiterGlo (Promega). This is a luminescent method that determines the number of viable cells in culture based on quantification of the ATP present. Luminescence was recorded after 10 min of incubation using a microplate luminometer (FluoStar Optima, BMG Labtech). Three independent experiments were done for each experimental condition each times.
Animal models and xenograft assay Before xenograft experiments, luciferase gene was transduced in SK-BR-3 (AF6-4088 or lacZ) cells. Approximately 70% confluent cells (10 6 cells) were incubated with a 1:3 precipitated mixture of lentiviral supernatants Lenti-LUC-vesicular stomatitis virus G (Vector Core, University of Michigan, MI, USA) and culture medium, for overnight incubation. Fresh medium was replenished at this time. The following day, the cells were harvested by trypsin/EDTA and subcultured at a ratio of 1:3. After 1-week incubation, the luciferase expression was detected by adding 2 ml D-luciferin (Promega).
Tumorigenicity of SK-BR-3 (AF6-4088 or lacZ) cells was assessed in independent sets of five immunodeficient non-obese diabetic/severe combined immunodeficiency/gamma cnull (NOD/SCID/gamma cnull or NOG) mice (Jackson Laboratory, Bar Harbor, ME, USA). Six-week-old NOG mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) during the implantation procedure. For tumor formation, 0.3 Â 10 6 SK-BR-3 cells in FBS were mixed with Matrigel (Becton Dickinson; 1:1) and injected orthotopically into the fourth abdominal mammary gland. To ensure that equivalent amount of cells were xenografted in mice, bioluminescence quantification was performed on anesthetized animals 5 days after xenograft. Bioluminescence images were acquired using a cooled intensified charge-coupled device camera (Photon Imager, Biospace Lab, France). Tumor volume was determined weekly by measuring the tumors in two dimensions using a calliper. Volume (V) was determined by the following equation, where L is length and W is width: V ¼ (L Â W 2 ) Â 0.5.
Statistical analyses
Data are presented as mean ± s.e.m. and were analyzed by Mann-Whitney tests using Prism software as indicated. Po0.05 was considered statistically significant. Tumor diameter and corresponding standard errors were determined for each experiment. Statistical analyses were based on paired t-tests.
